Expression of p53, p27 and Jab1 protein in epithelial ovarian tumors
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Lee, W. S. | - |
dc.contributor.author | Park, E. S. | - |
dc.contributor.author | Kim, D. H. | - |
dc.contributor.author | Kim, T. H. | - |
dc.contributor.author | Lee, H. H. | - |
dc.contributor.author | Chung, S. H. | - |
dc.date.accessioned | 2021-08-12T04:44:33Z | - |
dc.date.available | 2021-08-12T04:44:33Z | - |
dc.date.issued | 2012 | - |
dc.identifier.issn | 0392-2936 | - |
dc.identifier.uri | https://scholarworks.bwise.kr/sch/handle/2021.sw.sch/15978 | - |
dc.description.abstract | Objective: The study aimed to investigate expression of p53, p27 and Jun activation domain-binding protein 1 (Jab1) proteins in epithelial ovarian tumors and the values of these factors as discriminating markers for the transformation of borderline tumors to cancers. Methods: Forty-seven cases of paraffin-embedded tissues of epithelial ovarian tumors including 22 cases of benign ovarian tumors, nine cases of borderline tumors, and 16 cases of invasive cancers were used to evaluate expression of p53, p27 and Jab1 proteins by immunohistochemical methods. Results: p53 protein was expressed in 13.6% of the benign tumors, 44.4% of the borderline tumors and 62.5% of the malignant tumors and p27 protein was expressed in 95.5% of the benign tumors, 66.7% of the borderline tumors, and 37.5% of the malignant tumors. Expression of Jab1 protein was observed in 22.7% of the benign tumors, 77.8% of the borderline tumors and 62.5% of the malignant tumors. Expressions of p53, p27 and Jab1 proteins in malignant tumors were all higher than in benign tumors and the expression of p27 protein in malignant tumors was lower than in benign tumors (p < 0.05). Expression of Jab1 protein in borderline tumors was significantly higher than in benign tumors (p < 0.05). Conclusions: Expression of p53, p27 and Jab1 proteins can be used to discriminate between benign and malignant tumors in epithelial ovarian tumors. | - |
dc.format.extent | 5 | - |
dc.language | 영어 | - |
dc.language.iso | ENG | - |
dc.publisher | S O G Canada Inc. | - |
dc.title | Expression of p53, p27 and Jab1 protein in epithelial ovarian tumors | - |
dc.type | Article | - |
dc.publisher.location | 캐나다 | - |
dc.identifier.scopusid | 2-s2.0-84866062317 | - |
dc.identifier.wosid | 000307158700003 | - |
dc.identifier.bibliographicCitation | European Journal of Gynaecological Oncology, v.33, no.4, pp 358 - 362 | - |
dc.citation.title | European Journal of Gynaecological Oncology | - |
dc.citation.volume | 33 | - |
dc.citation.number | 4 | - |
dc.citation.startPage | 358 | - |
dc.citation.endPage | 362 | - |
dc.type.docType | Article | - |
dc.description.isOpenAccess | N | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.relation.journalResearchArea | Oncology | - |
dc.relation.journalResearchArea | Obstetrics & Gynecology | - |
dc.relation.journalWebOfScienceCategory | Oncology | - |
dc.relation.journalWebOfScienceCategory | Obstetrics & Gynecology | - |
dc.subject.keywordPlus | CYCLE INHIBITOR P27(KIP1) | - |
dc.subject.keywordPlus | CDK INHIBITOR | - |
dc.subject.keywordPlus | PROGNOSTIC MARKER | - |
dc.subject.keywordPlus | BREAST-CANCER | - |
dc.subject.keywordPlus | OVEREXPRESSION | - |
dc.subject.keywordPlus | CARCINOMAS | - |
dc.subject.keywordPlus | DEGRADATION | - |
dc.subject.keywordPlus | SURVIVAL | - |
dc.subject.keywordPlus | MUTATION | - |
dc.subject.keywordPlus | BENIGN | - |
dc.subject.keywordAuthor | p53 | - |
dc.subject.keywordAuthor | p27 | - |
dc.subject.keywordAuthor | Jab1 | - |
dc.subject.keywordAuthor | Borderline tumor | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
(31538) 22, Soonchunhyang-ro, Asan-si, Chungcheongnam-do, Republic of Korea+82-41-530-1114
COPYRIGHT 2021 by SOONCHUNHYANG UNIVERSITY ALL RIGHTS RESERVED.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.